Carl L Gordon
CIK 1282930 · last filed 2026-09-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMRN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
54TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADRX | Director | 8,974,061 | — | — | $16.15M | 1 | 2026-09-30 |
| ETRA | Director | 2,002,310 | — | — | $20.00M | 1 | 2026-09-23 |
| BlossomHill Therapeutics, Inc. (BLSM) Delisted | Director | 2,089,279 | $16.39 | $34.24M | $10.00M | 2 | 2026-08-12 |
| SCTX | Director | 348,825 | $15.60 | $5.44M | $15.00M | 2 | 2026-07-29 |
| CMPX | Director | 15,219,994 | $0.75 | $11.37M | $14.98M | 10 | 2026-01-05 |
| KROS | Director | 764,405 | $11.33 | $8.66M | -$5.00M | 8 | 2025-12-18 |
| MBX | Director | 747,887 | $50.29 | $37.61M | $14.02M | 3 | 2025-02-19 |
| NCNA | Director | — | $1.04 | — | $0 | 1 | 2024-08-23 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | 1,968,480 | $52.95 | $104.23M | $17.44M | 9 | 2024-07-17 |
| ACET | Director | 41,154 | $3.94 | $162.1K | $9.33M | 10 | 2024-06-07 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 0 | $4.06 | $0 | $14.49M | 9 | 2024-02-14 |
| AVBP | Director | 1,513,664 | $15.36 | $23.25M | $8.00M | 1 | 2024-01-31 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 1,368,339 | $2.65 | $3.63M | $24.75M | 9 | 2023-06-13 |
| Disc Medicine, Inc. (GMTX) Delisted | Director | — | $13.50 | — | $0 | 1 | 2021-10-06 |
| ORIC | Director | 2,212,571 | $8.96 | $19.81M | -$10.67M | 8 | 2021-06-17 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | 13,822,463 | — | — | $15.00M | 2 | 2020-06-19 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 2,027,550 | $76.01 | $154.11M | $6.48M | 2 | 2020-06-17 |
| ALEC | Director | 94,075 | $1.83 | $172.2K | $7.82M | 2 | 2019-05-14 |
| ARMO BioSciences, Inc. (ARMO) Delisted | Director | 0 | — | — | $0 | 3 | 2018-06-22 |
| X4 Pharmaceuticals, Inc (ASNS) Delisted | Director | 3,115 | $0.08 | $243 | $5.00M | 4 | 2018-06-07 |
| NTLA | Director | 2,662,180 | $11.26 | $29.98M | $4.50M | 3 | 2017-05-19 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 12,193 | $0.88 | $10.7K | $7.70M | 1 | 2016-06-29 |
| AMRN | Director | 285 | $12.09 | $3.4K | -$108.10M | 13 | 2012-09-05 |
| PCRX | Director | 2,828,941 | $36.38 | $102.92M | $3.75M | 1 | 2011-02-10 |
| GNOM | Director | — | $66.46 | — | $0 | 1 | 2010-12-02 |
Recent Filings · Page 5 of 12
111 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-11-10 | CMPX | Buy (P) | +402,000 | $1.29M | EDGAR |
| 2022-11-09 | Theseus Pharmaceuticals, Inc. (THRX) Delisted | Buy (P) | +192,000 | $1.00M | EDGAR |
| 2022-08-18 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Buy (P) | +3,690,000 | $8.93M | EDGAR |
| 2022-06-21 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-15 | Kinnate Biopharma Inc. (KNTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-13 | Theseus Pharmaceuticals, Inc. (THRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-03 | KROS | Grant (A) | — | $0 | EDGAR |
| 2022-06-03 | ACET | Grant (A) | — | $0 | EDGAR |
| 2022-05-13 | CMPX | Buy (P) | +192,516 | $420.5K | EDGAR |
| 2022-05-10 | CMPX | Buy (P) | +125,359 | $197.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.